

Synopsis

Identifier: 2011N122963_00

Study Number: EMI114238 and EMI113236

Title: EMI114238: An open-label study to evaluate the utility of the apoptosis imaging biomarker [¹⁸F]ML10 to assess the response to chemotherapy in patients with Non-Hodgkin's Lymphoma(NHL).

EMI113236: A Positron Emission Tomography (PET) Study to evaluate [¹⁸F]ML10 as an imaging agent for tumour apoptosis.

Investigator(s):

Dr. PPD

Study center(s):

GlaxoSmithKline Clinical Imaging Centre (CIC), Hammersmith Hospital, London

Publication(s):

None published at time of this report.

Study period:

EMI114238:

Initiation Date: 15 NOV 2010

Early Termination Date: 26 JUL 2011

EMI113236:

Initiation Date: 07 DEC 2009

Early Termination Date: 22 JUL 2011

Phase of development: I